Home Regulatory and Market Updates
Regulatory and Market Updates
What has changed in compounding rules, coverage and pricing — and what to verify yourself.
This section tracks the regulatory and commercial context around tirzepatide: the compounding framework, enforcement against misleading marketing, shortage status, coverage policy and brand self-pay pricing.
Everything here moves. Each page states what to verify and where, because a summary written today is a historical document within months.
Updates
FDA and Compounded Tirzepatide
The rules have moved repeatedly since the shortage. Here is the shape of the current position.
Compounded GLP-1 Marketing Enforcement
The recurring violation is language that makes a compounded preparation sound approved.
Tirzepatide Shortage Status
Supply status is the switch that governs how much compounding can lawfully happen.
Medicare GLP-1 Coverage
Historically excluded, now partially addressed — and the details determine whether you qualify.
Brand Self-Pay Pricing
A direct-to-patient channel priced well below retail and well above compounded.
Oral GLP-1 Pills
A daily tablet changes the competitive floor without matching injectable tirzepatide's effect size.
GLP-1 Coverage Withdrawals
Large employers and plans have repeatedly narrowed weight-management coverage, and patients absorb it mid-treatment.
Counterfeit Tirzepatide Alerts
Falsified product and research-labeled peptide are two different problems with the same outcome.
Primary sources
Clinical, dosing and regulatory statements on this page rest on the documents below. Links go to the publisher, not to a summary of it. Prices are not sourced here — they carry a verification date instead, and the reason is set out in the source ledger.
- ZEPBOUND (tirzepatide) full prescribing information — DailyMed, US National Library of Medicine. Dose ladder, contraindications, warnings, storage.
- FDA’s concerns with unapproved GLP-1 drugs used for weight loss — US Food and Drug Administration. Compounded GLP-1 risks, API import alert, cold-chain complaints.
- FD&C Act provisions that apply to human drug compounding — US Food and Drug Administration. Why a compounded preparation is lawful without being FDA-approved.
- Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1) — N Engl J Med 2022;387:205-216. Registration NCT04184622. The weight-reduction and adverse-event figures used across this site.
- The full source ledger — every primary source, what it supports, the date we read it, and the claims we deliberately do not source.